A distinct difference between the clinical application of personalized vaccines and our model system was our ability to functionally screen neoantigens for CD8+ and CD4+ T cell responses by IFN-γ ELISpot specific to the Panc02 tumor line. This evidence concerns the gene CD8A and neoplasm.